|Description||NPS-2143 (SB-262,470A) is a calcilytic drug which acts as an antagonist at the Calcium-sensing receptor (CaSR), and consequently stimulates release of parathyroid hormone. Calcilytic drugs have been researched as potential treatments for osteoporosis, and as the first such compound developed, NPS-2143 is still widely used in research into the CaSR receptor as well as design of newer calcilytic agents.|
|Synonyms||NPS2143 hydrochloride; NPS 2143 hydrochloride|
Evocalcet is a calcium-sensing receptor agonist under the development of Kyowa Hakko Kirin. Phase III clinical trials for Secondary hyperparathyroidism are on-g...
Cinacalcet HCl represents a new class of compounds for the treatment of hyperparathyroidism.
Cinacalcet is the first calcimimetic drug approved by the United States Food and Drug Administration for the treatment of secondary hyperparathyroidism in patie...
Calcium-Sensing Receptor Antagonists I
Calcium-Sensing Receptor Antagonists I is an antagonist of calcium-sensing parathyroid hormone receptors.
Etelcalcetide is a calcium-sensing receptor agonist as a D-amino peptide calcimimetic for the treatment of secondary hyperparathyroidism. It can bind to and act...
AC 265347 is a CaSR biased allosteric modulator (pEC50 = 7.8-8.1) that bias signaling towards the accumulation of PERK1/2 and IP1. AC 265347 stimulates CaSR sig...
NPS-2143 (SB-262,470A) is a calcilytic drug which acts as an antagonist at the Calcium-sensing receptor (CaSR), and consequently stimulates release of parathyro...
CaSR antagonist 18c
A calcium-sensing receptor (CaSR) antagonist (IC50 = 76 nM) potentially used as an anabolic agent for the treatment of osteoporosis.